Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)

NCT07293247 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT07293247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07293247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
October 14, 2026
Completion date
March 1, 2032
Enrollment
164 (estimated)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-small cell carcinoma